Ind-Swift Laboratories Ltd has posted a 15.52 per cent increase in its profit-after-tax at Rs 28.44 crore for the third quarter ended December 31, 2011 compared with Rs 24.62 crore in the corresponding period last fiscal.
According to a company statement, the total revenue increased 15.7 per cent to Rs 358.80 crore from Rs 310.11 crore.
Commenting on the results, the company Vice-Chairman, Mr N.R. Munjal, said: “Our growth in profits is as per our expectations. Our growth plans for the last quarter of this year as well as over the next three years are in place.”
During the quarter, the company’s export turnover was Rs 176.55 crore.
“The company got the KFDA (Korean FDA) approval and PMDA (Pharmaceutical and Medical Devices Agency Japan) approval this year and is supplying commercial quantities of its key molecules to USA and Japan,” the company said.
The company is a manufacturer of active pharmaceutical ingredients and advanced intermediates.
Ind-Swift Laboratories scrips were trading at Rs 31.80 per share in the afternoon trade on the BSE, down 1.09 per cent from their previous close.